Carcinosarcoma: all 76 studies

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C TrialNot yet recruitingNCT07723235Not applicable
• A Study of PHST001 in Advanced Solid TumorsRecruitingNCT06840886Phase 1
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformRecruitingNCT06349642
• Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial CancerRecruitingNCT05646316Phase 3
• ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerRecruitingNCT05542407Phase 1
• Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaRecruitingNCT05537844
• Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringRecruitingNCT05500391Phase 2
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
• GISAR German Interdisciplinary Sarcoma RegistryRecruitingNCT04122872
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
• ZW25 in Women With Endometrial CancersCompletedNCT04513665Phase 2Results posted
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerActive, not recruitingNCT03914612Phase 3Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicableResults posted
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaTerminatedNCT03610490Phase 2Results posted
• Vorinostat (SAHA) in Uterine SarcomaTerminatedNCT03509207Phase 2Results posted
• A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaCompletedNCT03395080Phase 2Results posted
• Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerActive, not recruitingNCT03367741Phase 2Results posted
• A Study of Nivolumab in Selected Uterine Cancer PatientsCompletedNCT03241745Phase 2Results posted
• Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryCompletedNCT03206177Phase 1Results posted
• A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerCompletedNCT03015129Phase 2Results posted
• Suitability of DCE-MRI for Detection of Vascular Changes After VBTCompletedNCT01991808Not applicableResults posted
• Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine CancerTerminatedNCT01367301Not applicableResults posted
• Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01247571Phase 2Results posted
• Ixabepilone in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01168232Phase 2Results posted
• Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the UterusTerminatedNCT01061606Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerStatus unknownNCT00954174Phase 3Results posted
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2Results posted
• Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian CancerCompletedNCT00511992Phase 2Results posted
• Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the UterusCompletedNCT00502203Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT00478426Phase 2Results posted
• Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the UterusCompletedNCT00476086Phase 2Results posted
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaCompletedNCT00390234Phase 2Results posted
• Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaCompletedNCT00245102Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Recurrent Uterine CancerCompletedNCT00238121Phase 2Results posted
• Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00114218Phase 2Results posted
• Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine CancerCompletedNCT00112489Phase 2Results posted
• Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00075400Phase 2Results posted
• Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the UterusCompletedNCT00025506Phase 2Results posted
• Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
• Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or CarcinosarcomaStatus unknownNCT05265793Phase 2
• (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1
• Nivolumab for Recurrent/Metastatic CarcinosarcomaStatus unknownNCT05224999Phase 2
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerTerminatedNCT04906382Early Phase 1
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin DamageTerminatedNCT04688749
• Expanded Access Use of DKN-01 for the Treatment of Advanced Solid TumorsNo longer availableNCT04681248
• Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.CompletedNCT04458597Not applicable
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 3
• ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2
• Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or ChemotherapyWithdrawnNCT03933761Phase 2
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
• Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological CancerWithdrawnNCT03902379Not applicable
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
• Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 2
• Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT03552471Phase 1
• Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)CompletedNCT02993705Phase 2
• Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast CancerCompletedNCT02983279Not applicable
• microRNA Profiles Identification in Adeno Carcinoma Prostate CancerStatus unknownNCT02964351
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Pazopanib Vs. Pazopanib Plus GemcitabineActive, not recruitingNCT02203760Phase 2
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or CarcinosarcomaStatus unknownNCT01454479Phase 1
• Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving ChemotherapyCompletedNCT01080521
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsCompletedNCT00815945Phase 2
• Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma CancerCompletedNCT00352300Phase 1
• Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
• Topotecan in Treating Patients With Recurrent or Refractory Cancer of the UterusTerminatedNCT00003156Phase 2
• Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the UterusCompletedNCT00003128Phase 3
• Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the UterusCompletedNCT00002546Phase 3

← Carcinosarcoma overview